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Abstract
Background: Anxiety disorders are common in early adulthood, but general population studies concerning the
treatment adequacy of anxiety disorders taking into account appropriate pharmacological and psychological
treatment are scarce. The aims of this study were to examine treatments received for anxiety disorders in a Finnish
general population sample of young adults, and to define factors associated with receiving minimally adequate
treatment and with dropping out from treatment.
Methods: A questionnaire containing several mental health screens was sent to a nationally representative two-stage
cluster sample of 1894 Finns aged 19 to 34 years. All screen positives and a random sample of screen negatives were
invited to a mental health assessment including a SCID interview. For the final diagnostic assessment, case records
from mental health treatments for the same sample were obtained. This article investigates treatment received,
treatment adequacy and dropouts from treatment of 79 participants with a lifetime anxiety disorder (excluding those
with a single specific phobia). Based on all available information, receiving antidepressant or buspirone medication for
at least 2 months with at least four visits with any type of physician or at least eight sessions of psychotherapy within
12 months or at least 4 days of hospitalization were regarded as minimally adequate treatment for anxiety disorders.
Treatment dropout was rated if the patient discontinued the visits by his own decision despite having an adequate
treatment strategy according to the case records.
Results: Of participants with anxiety disorders (excluding those with a single specific phobia), 41.8 % had received
minimally adequate treatment. In the multivariate analysis, comorbid substance use disorder was associated with
antidepressant or buspirone medication lasting at least 2 months. Those who were currently married or cohabiting
had lower odds of having at least four visits with a physician a year. None of these factors were associated with the
final outcome of minimally adequate treatment or treatment dropout. Participants with comorbid personality disorders
received and misused benzodiazepines more often than others.
Conclusions: More efforts are needed to provide adequate treatment for young adults with anxiety disorders.
Attention should be paid to benzodiazepine prescribing to individuals with personality disorders.
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Background
Anxiety disorders are among the most prevalent mental
disorders worldwide [1–3], and they typically affect
young people [1]. In the World Mental Health Survey,
their lifetime prevalence varied from 4.8 % in China to
31.0 % in the United States [1]. The impact of chronic
anxiety disorders on quality of life is significant: among
Finnish Health 2000 survey participants aged over 30 years,
chronic anxiety disorders and dysthymia were associated
with the largest loss of HRQoL (health-related quality of
life) among mental disorders [4]. When 29 chronic condi-
tions were studied, anxiety disorders had the second lar-
gest negative impact on HRQoL just after Parkinson’s
disease [5].
According to previous studies, anxiety disorders in
the general population tend to be under-diagnosed [6]
and under-treated [7–9] and individuals with anxiety
disorders often experience long delays in seeking treat-
ment [10, 11]. The prevalence of service use for mental
health problems during the last 12 months varied from
20.6 to 44.9 % among respondents with anxiety disor-
ders [7, 8, 12–15].
General population studies concerning the treatment
adequacy of anxiety disorders taking into account ap-
propriate pharmacological and psychological treatment
are scarce, while the criteria for minimally adequate
treatment have likewise varied [7, 15–17]. In most of
the studies, anxiolytic medication was considered an
adequate treatment, with benzodiazepines still being
widely used by clinicians in spite of the controversy
around possible physical dependency and an association
with worse long-term outcomes [18, 19].
Mental health treatment dropout is a common prob-
lem [20–23] that may negatively affect the treatment
outcome [24] and indicate poor functioning of the health
care system [25]. Establishing which patient related
factors affect discontinuation would provide important
information for improving mental health services.
This study uses a nationwide, representative population-
based sample of young Finnish adults aged 20–34 years.
The aims of this study were to describe the frequency and
the type of treatment received for anxiety disorders and to
describe treatment adequacy and discontinuation and
socio-demographic and clinical features affecting them
among young adults.
Methods
Sample
Data were derived from the Mental Health in Early
Adulthood in Finland (MEAF) study. The methods have
been reported in detail elsewhere [26, 27]. Briefly, MEAF
was based on a nationally representative two-stage cluster
sample (n = 1894) of young adults aged 18–29 years taken
from the Health 2000 study, which was a comprehensive
health survey. The original young adult assessment was
carried out in 2001. There were also questions related to
mental health in the Health 2000 young adult protocol,
though a structured diagnostic interview was not con-
ducted [28–30]. Therefore, a substudy focusing on mental
health (MEAF) was carried out [26, 27].
The study flow of the MEAF study is presented in the
Additional file 1. A questionnaire including several scales
assessing mental health and substance use was mailed 2–4
years after the original study to all living members of the
sample, excluding those who had refused further contacts.
All screen-positive and a random subsample of screen-
negative participants were invited to the mental health
interview. Information from the Finnish National Hospital
Discharge Register (NHDR) was used to identify all per-
sons who had received hospital treatment due to any
mental disorder [International Classification of Diseases
(ICD)-10 section F, ICD-8 and ICD-9 290–319] and these
were also asked to participate in the interview. The
screening procedure has been described in detail previ-
ously [26, 27].
Ethics, consent and permissions
The ethics committees of the National Institute for Health
and Welfare and the Hospital District of Helsinki and
Uusimaa approved the Health 2000 survey and the MEAF
reassessment. Participants gave written informed consent
[26, 28].
Mental health assessment
The mental health interview was conducted using the
research version of the Structured Clinical Interview for
DSM-IV (SCID-I) [31], which included the SCID Screen-
ing module at the beginning to enhance reliability [32],
as well as the sections on mood, psychotic, substance
use, anxiety and eating disorders. The interview included
questions on socio-demographic factors and treatment
received for mental health problems. Experienced re-
search nurses or psychologists attended a 1-week training
course and had regular follow-up sessions to prepare them
to carry out the interviews, which were then reviewed to-
gether with a psychiatrist.
Final diagnostic assessment
For the final diagnostic assessment, all case records from
hospital and outpatient treatment contacts were obtained
with the participant’s approval. The Finnish Ministry of
Social Affairs and Health gave permission to view the case
records of non-participants, excluding those who had re-
fused any participation in the Health 2000 study. Four
experienced clinicians (J.S., T.A.-S., S.S., J.P.) made the
final best-estimate diagnoses using DSM-IV-TR criteria,
based on all available systematically evaluated information
from the interview and/or case records. Disorders not
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covered by SCID-I, e.g. personality disorders, were also
evaluated [26].
As reported previously, the lifetime prevalence of anxiety
disorders (i.e. panic disorder, agoraphobia, obsessive-
compulsive disorder, social phobia, specific phobia, post-
traumatic stress disorder, generalized anxiety disorder,
anxiety disorder NOS) in this sample was 12.6 % [26]. This
paper investigates this subgroup of 92 participants after
excluding those with a diagnosis of schizophrenia spectrum
psychotic disorders (3 persons).
Use of mental health services and treatment received
Information on treatment received for anxiety disorders
was gathered from mental health interviews and case re-
cords. We evaluated the visits and medication use for anx-
iety disorders during the 12 months that a participant was
most intensively treated. All data were collected on both
the most recent and the most intensive treatment period
for anxiety disorder. However, the present paper focuses
on the most recent treatment period, since our aim was to
investigate the typical and the most recent functioning of
the health care system. Results concerning the most inten-
sive treatment period are available in Additional files 2, 3,
4, 5 and 6.
It has been previously observed that patients with
isolated specific phobias very rarely seek professional
help [33]. Also in our sample, participants with specific
phobia more often had no treatment than others (Table 3).
Due to the lesser clinical significance and a different treat-
ment model [34, 35], we excluded those whose only anx-
iety disorder was specific phobia (13 subjects). The final
analysis of treatments received therefore included 79
participants.
Criteria for minimally adequate treatment
Criteria for minimally adequate treatment were deter-
mined according to evidence-based guidelines [34, 36–42]
and were the same as those used in the European
ESEMeD and the National Comorbidity Survey Replica-
tion [43, 44], except for hospital treatment and anxio-
lytic medication. As the benefits and disadvantages of
long-lasting use of benzodiazepines are controversial,
we regarded only the use of antidepressant or buspirone
for at least 2 months as an appropriate pharmacotherapy,
and studied the use and misuse of benzodiazepines separ-
ately. Hospitalizations have not been used as an adequacy
criterion in previous surveys. However, because we had
accurate information about hospitalizations based on the
national hospital discharge register and corresponding
case records, we used for at least 4 days of hospitalizations
for anxiety symptoms as an adequacy criterion. Based on
the information in the case records and the fact that
evaluation period in Finland is 4 days, we considered it
sufficient to assess the diagnosis as well as plan and start a
treatment. On the other hand, this time limit excluded for
example short visits in the emergency department.
Guideline-concordant treatment was defined as follows:
1) Pharmacotherapy: use of antidepressant or
buspirone for at least 2 months and at least four
visits within 12 months with a physician for anxiety
disorders. Included in visits were telephone
consultations between patient and physician, as well
as consultations between health care professionals
and the treating physician concerning the patient’s
treatment.
2) Psychotherapy: at least eight sessions within
12 months with a psychiatrist, psychologist or
psychotherapist in any settings or with another
professional in a psychiatric clinic for anxiety
disorders.
3) Hospital treatment: at least 4 days of hospitalization
for anxiety disorders.
A final outcome of minimally adequate treatment was
recorded if pharmacotherapy or psychotherapy or hos-
pital treatment was defined to be adequate.
Benzodiazepine misuse was recorded if a subject had a
diagnosis for benzodiazepine abuse or dependence or had
told about misuse in the interview or during the treatment
period. We took into account only misuse during the
index treatment period.
Treatment dropout was recorded when the treatment
strategy was assessed to be adequate according to the
case records but the patient discontinued the visits by
his own volition.
Sociodemographic, disorder-specific and comorbidity
factors
We studied the relationship between socio-demographic
factors and treatment using the following variables: gender,
marital status, age at the time the MEAF-questionnaire
was sent, basic education and current employment. Only
the effect of basic education was examined, since some of
the younger members of the cohort had not yet finished
their vocational or higher education.
The effect of comorbid psychiatric disorders on treat-
ment received, treatment adequacy and dropouts from
treatment was studied using the following disorder
categories: mood disorders, substance use disorders,
personality disorders and other disorders (psychotic,
eating, sleeping, adjustment and impulse control disor-
ders). We also studied if the number of different anx-
iety disorders (one or more) affected treatment.
Statistical analysis
Standard statistical methods were used to generate de-
scriptive statistics. Since the analysis was limited to the
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subgroup of participants with anxiety disorders only,
we did not use survey weights in the analysis. We ana-
lyzed the associations of socio-demographic factors and
comorbid psychiatric disorders with the treatments re-
ceived. The relationship of all these variables was ex-
amined separately for different components of care, i.e.
pharmacotherapy with antidepressants and buspirone,
benzodiazepine use and misuse, physician visits, psycho-
therapy, treatment adequacy and dropout from treatment.
Differences were tested using the χ2 or Fisher’s exact tests.
Logistic regression analysis was used to identify vari-
ables independently associated with the type and ad-
equacy of treatment. Gender, basic education, marital
status and different comorbid disorders were entered
simultaneously into a logistic regression model to ex-
plore the factors affecting treatment. All statistical tests
were two-tailed, and values of p < 0.05 were considered
statistically significant. We used the SAS 9.3 statistical
package in the analyses.
Results
Participants
Male participants with any lifetime diagnosis of anxiety
disorder numbered 26 (28.3 %) and female participants
66 (71.7 %). There were no statistically significant differ-
ences in socio-demographic factors between genders,
but men had more substance use disorders (Table 1).
The most common anxiety disorder was panic disorder,
affecting 27.2 % of participants, followed by social phobia
(25.0 %), anxiety disorder NOS (25.0 %) and specific
phobia (20.7 %). Less common were agoraphobia without
panic disorder (7.6 %), posttraumatic stress disorder
(6.5 %), obsessive-compulsive disorder (5.4 %), and gener-
alized anxiety disorder (3.3 %) (Table 2).
Participants with specific phobia had statistically sig-
nificantly more often no treatment than others with
anxiety disorder, whereas participants with anxiety dis-
order NOS were less often without treatment (Table 3).
After excluding those whose only anxiety disorder was
Table 1 Socio-demographic factors and comorbid psychiatric disorders of participants with a lifetime diagnosis of anxiety disorder
All Men Women
100.0 % N = 92 28.3 % N = 26 71.7 % N = 66
Variable Category % N % N % N p*
Age <25 years 19.6 18 15.4 4 21.2 14
25–29 years 40.2 37 42.3 11 39.4 26
≥30 years 40.2 37 42.3 11 39.4 26 0.818
Basic education Less than high school 52.8 47 69.6 16 47.0 31
High school 47.2 42 30.4 7 53.0 35 0.062
Married or cohabiting Yes 66.3 59 56.5 13 69.7 46
No 33.7 30 43.5 10 30.3 20 0.250
Current employment Employed 56.2 50 69.6 16 51.5 34
Studentc 18.0 16 21.7 5 16.7 11
Unemployed 11.2 10 8.7 2 12.1 8
Othera 14.6 13 0.0 0 19.7 13 0.077**
Comorbid mood disorder Yes 58.7 54 61.5 16 57.6 38
No 41.3 38 38.5 10 42.4 28 0.728
Comorbid personality disorder Yes 21.7 20 30.8 8 18.2 12
No 78.3 72 69.2 18 81.8 54 0.188
Comorbid substance abuse or
dependence (any substance)
Yes 28.3 26 57.7 15 16.7 11
No 71.7 66 42.3 11 83.3 55 <0.0001
Comorbid other disorderb Yes 18.5 17 7.7 2 22.7 15
No 81.5 75 92.3 24 77.3 51 0.137
aOf the other group, 10 (76.9 %) were at home taking care of household and family members, 2 (15.4 %) were on disability pension or sick leave and 1 (7.7 %)
was on return to work trial after sickness absence
bPsychotic, eating, sleeping, adjustment or impulse control disorder lifetime
cStudents in vocational schools or universities
*The p-values indicate a significance of the difference between genders in the distribution of each category tested by χ2- or Fisher’s exact test. P-values < 0.05
in boldface
**Fisher’s exact test was used in the analysis
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specific phobia, we had 22 male (27.9 %) and 57 (72.2 %)
female participants.
Treatment received and treatment adequacy
After excluding those with a single specific phobia,
70.9 % of participants had had some kind of contact
with the health care system for their anxiety disorders.
More than two thirds had visited a physician, and
36.4 % had had at least four visits within 12 months.
More than half had been prescribed an antidepressant
or buspirone, and 43.4 % had used them for at least
2 months. Guideline-concordant pharmacotherapy includ-
ing also physician visits was received by 26.6 % of partici-
pants. 57.9 % of subjects had attended psychotherapy
sessions, more than a third at least eight times within
12 months. Adequate hospital treatment was received by
10.1 % of the sample (8 participants). A total of 41.8 % of
subjects had received minimally adequate treatment.
11.0 % of participants had discontinued their visits despite
of a proper treatment plan (Table 4). Benzodiazepines
were prescribed to 34.6 % of participants, and 5.1 % had
misused them during the most recent treatment period
(Table 6).
Socio-demographic factors, treatment received and
dropouts
Those who were currently employed had less often had
four visits with a physician and eight psychotherapy ses-
sions a year than other groups in the bivariate analysis
(Table 4).
Marital status was statistically significantly associated
with appointments with physicians: those who were
Table 3 The percentage distribution of treatment contacts among participants with different anxiety disorders
Treatment No treatment
Variable Category % N % N p*
All 61.2 57 38.0 35
Gender Men 65.4 17 34.6 9
Women 60.6 40 39.4 26 0.671
Panic disorder with agoraphobia 79.0 15 21.1 4 0.087
Panic disorder without agoraphobia 66.7 4 33.3 2 1.000**
Agoraphobia without panic disorder 42.9 3 57.1 4 0.421**
Social phobia 65.2 15 34.8 8 0.710
Obsessive-compulsive disorder 60.0 3 40.0 2 1.000**
Posttraumatic stress disorder 66.7 4 33.3 2 1.000**
Generalized anxiety disorder 66.7 2 33.3 1 1.000**
Specific phobia 21.1 4 79.0 15 <0.0001
Anxiety disorder NOS 91.3 21 8.7 2 0.001
*The p-values indicate a significance of the difference between categories in the distribution of treatment tested by χ2- or Fisher’s exact test. P-values < 0.05
in boldface
**Fisher’s exact test was used in the analysis
Table 2 The percentage distribution of different anxiety disorders among the participants
All (N = 92) Men (N = 26) Women (N = 66) p*
Variable % N % N % N
Panic disorder with agoraphobia 20.7 19 23.1 6 19.7 13 0.718
Panic disorder without agoraphobia 6.5 6 3.9 1 7.6 5 0.672**
Agoraphobia without panic disorder 7.6 7 11.5 3 6.1 4 0.399**
Social phobia 25.0 23 38.5 10 19.7 13 0.061
Obsessive-compulsive disorder 5.4 5 3.9 1 6.1 4 1.000**
Posttraumatic stress disorder 6.5 6 0.0 0 9.1 6 0.179**
Generalized anxiety disorder 3.3 3 3.9 1 3.0 2 1.000**
Specific phobia 20.7 19 15.4 4 22.7 15 0.433
Anxiety disorder NOS 25.0 23 23.1 6 25.8 17 0.789
*The p-values indicate a significance of the difference between genders in the distribution of each category tested by χ2- or Fisher’s exact test. P-values < 0.05
in boldface
**Fisher’s exact test was used in the analysis
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Table 4 Sociodemographic factors, treatments received and dropouts during the most recent treatment episode for anxiety disordersh, i
Pharmacotherapy Visits with a physician Guideline concordant
pharmacotherapyc
Sessions of psychotherapy / a
year
Minimally adequate
treatmente
Treatment
dropoutf
Anya ≥2 months Anyb ≥4 times Anyd ≥8 times
Variable Category % N % N % N % N % N % N % N % N % N
All 51.3 40 43.4 33 68.8 53 36.4 28 26.6 21 57.9 44 34.2 26 41.8 33 11.0 8
Gender Male 59.1 13 54.6 12 71.4 15 42.9 9 36.4 8 71.4 15 33.3 7 45.5 10 9.5 2
Female 48.2 27 38.9 21 67.9 38 33.9 19 22.8 13 52.7 29 34.6 19 40.4 23 11.5 6
p* 0.387 0.212 0.763 0.468 0.222 0.140 0.921 0.680 1.000
Agegroup <25 years 66.7 10 60.0 9 78.6 11 42.9 6 40.0 6 71.4 10 57.1 8 60.0 9 7.7 1
25–29 years 45.5 15 39.4 13 61.8 21 29.4 10 23.5 8 51.5 17 12.1 4 29.4 10 12.5 4
≥30 years 50.0 15 39.3 11 72.4 21 41.4 12 23.3 7 58.6 17 48.3 14 46.7 14 10.7 3
p* 0.389 0.352 0.453 0.527 0.426 0.447 0.002 0.107 1.000g
Basic Less than high school 48.7 18 36.1 13 67.6 25 35.1 13 23.7 9 61.1 22 36.1 13 44.7 17 18.2 6
education High school 50.0 19 46.0 17 68.4 26 34.2 13 26.3 10 51.4 19 32.4 12 36.8 14 5.4 2
p* 0.907 0.393 0.937 0.933 0.791 0.401 0.741 0.484 0.136g
Current Employed 42.5 17 38.5 15 62.5 25 22.5 9 15.0 6 47.5 19 17.5 7 30.0 12 13.5 5
employment Student 71.4 10 57.1 8 71.4 10 57.1 8 42.9 6 69.2 9 53.9 7 50.0 7 14.3 2
Unemployed 44.4 4 44.4 4 62.5 5 62.5 5 44.4 4 66.7 6 55.6 5 66.7 6 12.5 1
Other 50.0 6 27.3 3 84.6 11 30.8 4 23.1 3 63.6 7 54.6 6 46.2 6 0.0 0
p* 0.331g 0.491g 0.517g 0.033g 0.084g 0.445g 0.008g 0.167 0.689g
Married or No 63.0 17 46.2 12 80.8 21 53.9 14 33.3 9 69.2 18 46.2 12 55.6 15 12.0 3
cohabiting Yes 41.7 20 38.3 18 61.2 30 24.5 12 20.4 10 48.9 23 27.7 13 32.7 16 11.1 5
p* 0.077 0.514 0.084 0.011 0.213 0.094 0.111 0.052 1.000g
aAntidepressant or buspirone prescribed
bAt least 1 visit with a physician a year
cAntidepressant or buspirone used for at least 2 months + 4 visits with a physician a year
dAt least 1 session of psychotherapy a year
eAntidepressant or buspirone used for at least 2 months + at least 4 visits with a physician a year or at least 8 sessions of psychotherapy a year or a hospitalization for anxiety disorders lasting for at least 4 days
fA participant discontinued the visits despite adequate treatment plan
gFisher’s exact test was used in the analysis
hParticipants with a single specific phobia were excluded
iA bivariate analysis
*The p-values indicate a significance of the difference between categories in a distribution of treatments and dropout tested by χ2- or Fisher’s exact test. P-values < 0.05 in boldface
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currently cohabiting had less often had at least four
visits with a physician a year in the bivariate analysis
(Table 4).
Age at the time of the study had an association with
psychotherapy sessions: the middle age group had had
less often than others at least 8 sessions of psychother-
apy a year (Table 4).
In our study group, 11.0 % of participants dropped out
of treatment. No associations were found between socio-
demographic factors and dropouts (Table 4).
Comorbid psychiatric disorders, treatment received and
dropouts
In the bivariate analysis, comorbid substance use
disorder was related to antidepressant or buspirone
medication for at least 2 months and receiving benzo-
diazepines (Tables 5 and 6). There was also an associ-
ation between comorbid substance use disorder and
receiving psychotherapy (Table 5).
Participants with comorbid personality disorders re-
ceived and misused benzodiazepines more often than
others according to the bivariate analysis (Table 6). An
association was also found between personality disorders
and visits with a physician at least four times within
12 months (Table 5).
No associations were found between comorbid disor-
ders and treatment dropouts (Table 5).
Factors associated with treatment in the multivariate
analyses
In the multivariate analysis, comorbid substance use dis-
order (OR 4.48, CI 1.11–18.08, P = 0.035) was associated
with antidepressant or buspirone medication lasting at
least 2 months (Table 7). Comorbid personality disorder
in turn was associated with increased odds for benzodi-
azepine medication (OR 4.77, CI 1.11–20.59, P = 0.036)
(Table 8). Those who were currently married or cohabit-
ing had lower odds of having at least four visits with a
physician a year (OR 0.27, CI 0.08–0.85, P = 0.025)
(Table 7). None of these factors explained the final out-
come of minimally adequate treatment, but the p-value
for the association between marital status and minimally
adequate treatment was close to being significant (OR
0.36, CI 0.12–1.05, P = 0.062) and was significant when we
studied the most intensive treatment episode (OR 0.33, CI
0.11–0.99, P = 0.048) (Table 7 and Additional file 5).
Discussion
In our study of a nationally representative sample of
young adults with anxiety disorder (excluding those with a
single specific phobia), 70.9 % had some kind of contact
with the health care system for their anxiety disorder, and
41.8 % had received minimally adequate treatment during
the most recent treatment period. In the adult sample of
the Health 2000 Survey, only 33.5 % of participants with
anxiety disorders had used health care services for mental
health problems during the preceding 12 months [8]. Ac-
cording to these figures young adults seek and receive
more treatment than older adults in Finland. The same
kind of trend was found in the treatment of depressive
disorders in the Health 2000 Survey, where 40.9 % of
young adults received minimally adequate treatment
during the last depressive episode, whereas only 18 %
of individuals with MDD aged over 30 had received min-
imally adequate treatment during the previous 12 months
[27, 45].
A comparison with previous surveys concerning
treatment adequacy is difficult because of the different
settings and criteria for minimally adequate treatment
and also a variation in diagnoses included in anxiety
disorders. In the NCS-R-survey, where the criteria of
minimally adequate treatment were very similar to ours,
33.8 % of treated patients (42.2 %) received minimally ad-
equate treatment, corresponding to a treatment adequacy
of about 14 % among all participants with anxiety disorders
[44]. Fernandez et al. obtained quite similar results in
Spain, where 30.7 % of treated patients (41.8 %) with any
anxiety disorder received minimally adequate treatment,
corresponding to about 13 % of all participants with
anxiety disorders [16]. Compared to these figures, the
situation is better for young adults in Finland. In a re-
cent German study, the proportion of people with life-
time anxiety disorder with a self-reported mental health
care contact was similar to ours, varying from 42.7 %
for obsessive-compulsive disorder to 69.2 % in general-
ized anxiety disorder [13].
The higher proportion of adequate treatment in our
study may partly be explained by our versatile informa-
tion search, which also included medical records. The
young age of our participants and the fact that we stud-
ied the most recent treatment episode also decreases
memory bias in this study. We included telephone con-
sultations by patient or another health care professional
as visits with a physician, which may slightly increase
the proportion of adequate treatment. Furthermore, we
defined hospitalization lasting at least 4 days as adequate
care. However, these cases were few (8 participants) and
almost all (7 participants) had also received adequate
treatment in outpatient care.
None of the factors chosen were related to the adequacy
of treatment. However, currently married or cohabiting
subjects had less often had physician visits in accordance
with guidelines according to the multivariate analysis. In
addition, those who were currently employed had less
often had physician visits and psychotherapy in accord-
ance with guidelines according to the bivariate analysis.
These figures may suggest that among the participants
with anxiety disorders there is a subgroup who has less
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Table 5 Comorbid disorders, treatments received and dropouts during the most recent treatment episode for anxiety disordersi, j
Pharmacotherapy Visits with a physician Guideline concordant
pharmacotherapyc
Sessions of psychotherapy / a
year
Minimally adequate
treatmente
Treatment
dropoutf
Anya ≥2 months Anyb ≥4 times Anyd ≥8 times
Variable Category % N % N % N % N % N % N % N % N % N
Comorbid Yes 54.2 26 45.8 22 71.7 33 41.3 19 31.3 15 58.3 28 35.4 17 45.8 22 13.6 6
mood No 46.7 14 39.3 11 64.5 20 29.0 9 19.4 6 57.1 16 32.1 9 35.5 11 6.9 2
disorders p* 0.519 0.579 0.502 0.272 0.243 0.919 0.772 0.362 0.465g
Comorbid Yes 65.2 15 63.6 14 77.3 17 50.0 11 39.1 9 78.3 18 39.1 9 47.8 11 4.8 1
substance use No 45.5 25 35.2 19 65.5 36 30.9 17 21.4 12 49.1 26 32.1 17 39.3 22 13.5 7
disorder p* 0.111 0.023 0.312 0.116 0.106 0.018 0.552 0.484 0.425g
Comorbid Yes 68.4 13 52.6 10 73.7 14 57.9 11 40.0 8 73.7 14 52.6 10 60.0 12 15.8 3
personality No 45.8 27 40.4 23 67.2 39 29.3 17 22.0 13 52.6 30 28.1 16 35.6 21 9.3 5
disorder p* 0.086 0.350 0.599 0.025 0.116 0.108 0.051 0.056 0.421g
Comorbid other Yes 56.3 9 40.0 6 56.3 9 56.3 9 37.5 6 50.0 8 43.8 7 50.0 8 6.3 1
disorderh No 50.0 31 44.3 27 72.1 44 31.2 19 23.8 15 60.0 36 31.7 19 39.7 25 12.3 7
p* 0.656 0.765 0.239g 0.063 0.343g 0.472 0.365 0.455 0.676g
More than 1 Yes 46.7 7 40.0 6 64.3 9 35.7 5 25.0 4 60.0 9 40.0 6 37.5 6 0.0 0
anxiety No 52.4 33 44.3 27 69.8 44 36.5 23 27.0 17 57.4 35 32.8 20 42.9 27 13.6 8
disorder p* 0.691 0.765 0.753g 0.956 1.000g 0.854 0.598 0.698 0.340g
aAntidepressant or buspirone prescribed
bAt least 1 visit with a physician a year
cAntidepressant or buspirone used for at least 2 months + 4 visits with a physician a year
dAt least 1 session of psychotherapy a year
eAntidepressant or buspirone used for at least 2 months + at least 4 visits with a physician a year or at least 8 sessions of psychotherapy a year or a hospitalization for anxiety disorders lasting for at least 4 days
fA participant discontinued the visits despite having an adequate treatment plan
gFisher’s exact test was used in the analysis
hPsychotic, eating, sleeping, adjustment or impulse control disorder lifetime
iParticipants with a single specific phobia were excluded
jA bivariate analysis
*The p-values indicate a significance of the difference between categories in a distribution of treatments and dropout tested by χ2- or Fisher’s exact test. P-values < 0.05 in boldface
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Table 6 Sociodemographic factors, comorbid disorders, benzodiazepine use and misuse during the most recent treatment episode
for anxiety disordersc,d
Benzodiazepine Benzodiazepine misuse
Not prescribed Prescribed No Yes
Variable Category % N % N % N % N
All 65.4 51 34.6 27 94.9 75 5.1 4
Gender Male 50.0 11 50.0 11 95.5 21 4.6 1
Female 71.4 40 28.6 16 94.7 54 5.3 3
p* 0.073 1.000a
Agegroup <25 years 73.3 11 26.7 4 100.0 15 0.0 0
25–29 years 69.7 23 30.3 10 97.1 33 2.9 1
≥30 years 56.7 17 43.3 13 90.0 27 10.0 3
p* 0.428 0.402a
Basic Less than high school 64.9 24 35.1 13 97.4 37 2.6 1
education High school 71.1 27 29.0 11 94.7 36 5.3 2
p* 0.566 1.000a
Current Employed 75.0 30 25.0 10 100.0 40 0.0 0
employment Student 57.1 8 42.9 6 92.9 13 7.1 1
Unemployed 55.6 5 44.4 4 100.0 9 0.0 0
Other 66.7 8 33.3 4 84.6 11 15.4 2
p* 0.485a 0.061a
Married or No 66.7 18 33.3 9 96.3 26 3.7 1
cohabiting Yes 68.8 33 31.3 15 95.9 47 4.1 2
p* 0.853 1.000a
Comorbid Yes 66.7 32 33.3 16 93.8 45 6.3 3
mood No 63.3 19 36.7 11 96.8 30 3.2 1
disorder p* 0.763 1.000a
Comorbid Yes 43.5 10 56.5 13 87.0 20 13.0 3
substance use No 74.6 41 25.5 14 98.2 55 1.8 1
disorder p* 0.009 0.072a
Comorbid Yes 31.6 6 68.4 13 80.0 16 20.0 4
personality No 76.3 45 23.7 14 100.0 59 0.0 0
disorder p* 0.0004 0.003a
Comorbid other Yes 50.0 8 50.0 8 81.3 13 18.8 3
disorderb No 69.4 43 30.7 19 98.4 62 1.6 1
p* 0.147 0.025a
More than 1 Yes 73.3 11 26.7 4 87.5 14 12.5 2
anxiety No 63.5 40 36.5 23 96.8 61 3.2 2
disorder p* 0.472 0.181a
aFisher’s exact test was used in the analysis
bPsychotic, eating, sleeping, adjustment or impulse control disorder lifetime
cParticipants with a single specific phobia were excluded
dA bivariate analysis
*The p-values indicate a significance of the difference between categories in a distribution of treatments and dropout tested by χ2- or Fisher’s exact test. P-values < 0.05
in boldface
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Table 7 Variables associated with treatments received during the most recent treatment period for anxiety disordersg, h
Pharmacotherapy Visits with a physician / a year Guideline-
concordant
pharmacotherapyc
Sessions of psychotherapy / a
year
Minimally
adequate
treatmente
Anya ≥2 months Anyb ≥4 times Anyd ≥8 times
Variable Category OR 95 % CI OR 95 % CI OR 95 % CI OR 95 % CI OR 95 % CI OR 95 % CI OR 95 % CI OR 95 % CI
Gender Male (ref.) 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 -
Female 1.19 0.34–4.14 1.06 0.29–3.90 1.95 0.50–7.64 1.16 0.30–4.56 0.72 0.18–2.87 1.18 0.31–4.47 1.50 0.38–5.92 1.18 0.33–4.18
Basic education Less than high school (ref.) 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 -
High school 1.33 0.42–4.18 3.08 0.86–11.04 1.42 0.41–4.97 0.92 0.25–3.35 1.57 0.40–6.09 1.04 0.31–3.45 1.12 0.32–3.94 0.71 0.22–2.30
Married or No (ref.) 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 -
cohabiting Yes 0.43 0.15–1.25 0.85 0.28–2.56 0.34 0.09–1.25 *0.27 0.08–0.85 0.66 0.20–2.11 0.35 0.11–1.14 0.39 0.12–1.21 0.36 0.12–1.05
Comorbid No (ref.) 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 -
mood disorder Yes 1.07 0.36–3.14 1.47 0.47–4.60 1.28 0.41–4.00 0.99 0.31–3.15 1.59 0.46–5.44 0.71 0.22–2.26 0.70 0.21–2.34 1.07 0.37–3.13
Comorbid substance No (ref.) 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 -
use disorder Yes 1.92 0.54–6.86 *4.48 1.11–18.08 2.46 0.59–10.30 1.46 0.39–5.48 1.78 0.46–6.95 3.21 0.81–12.75 1.27 0.33–4.82 0.98 0.28–3.42
Comorbid No (ref.) 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 -
personality disorder Yes 1.87 0.49–7.20 1.40 0.34–5.84 1.55 0.38–6.35 2.20 0.55–8.70 1.76 0.41–7.51 2.05 0.49–8.48 4.03 0.97–16.83 2.24 0.61–8.26
Comorbid No (ref.) 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 -
other disorderf Yes 0.89 0.23–3.41 0.51 0.12–2.12 0.26 0.06–1.10 2.36 0.59–9.45 1.48 0.35–6.22 0.43 0.11–1.77 1.02 0.25–4.11 1.24 0.32–4.72
More than 1 anxiety No (ref.) 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 - 1.00 -
disorder Yes 0.59 0.15–2.31 0.45 0.10–1.96 0.64 0.16–2.53 0.97 0.22–4.19 0.74 0.16–3.35 0.99 0.25–3.96 1.90 0.45–8.01 0.80 0.21–2.97
OR Adjusted odds ratio; 95 % CI 95 % confidence interval
*p < 0.05; **p < 0.01; ***p < 0.001. These p-values indicate a significance of the difference of the odds ratios between categories tested by χ2-test. Significant differences (p < 0.05) in boldface
aAntidepressant or buspirone prescribed
bAt least 1 visit with a physician a year
cAntidepressant or buspirone used for at least 2 months + 4 visits with a physician a year
dAt least 1 session of psychotherapy a year
eAntidepressant or buspirone used for at least 2 months + at least 4 visits with a physician a year or at least 8 sessions of psychotherapy a year or a hospitalization for anxiety disorders lasting for at least 4 days
fPsychotic, eating, sleeping, adjustment or impulse control disorder, lifetime
gParticipants with a single specific phobia were excluded
hAll the variables were entered simultaneously into a logistic regression model, adjusting for the other factors shown in the table
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severe illness, less disabilities, more social support and
good abilities to help themselves. This is supported by the
fact that anxiety disorders consist of several illnesses for
which the clinical significance may vary. However, despite
good social functioning, untreated illness may cause per-
sonal suffering and lead to disabilities.
Comorbid substance use disorder was related to both
antidepressant or buspirone medication lasting at least
2 months and benzodiazepine use, and the first difference
was statistically significant even after adjusting for other
factors. Moreover, comorbid personality disorder was as-
sociated with benzodiazepine use in the multivariate ana-
lysis and additionally with benzodiazepine misuse and
physician visits in accordance with guidelines in the bi-
variate analysis. So, there may be a trend to treat patients
with complicated illness more intensively. Unfortunately
this pursuit may sometimes lead to inappropriate use of
benzodiazepines.
Benzodiazepines had been prescribed to 34.6 % of
people with anxiety disorders, and benzodiazepine (BZD)
use was strongly associated with having a comorbid per-
sonality or substance use disorder. BZD misuse was infre-
quent, but our figure was probably an underestimate since
it was either based on self-report in the interview or diag-
nosed abuse/dependence by the treating physician. There
is evidence of short-term effectiveness of BZDS in panic
disorder, generalized anxiety disorder and to some extent
in social phobia, but BZDs are not effective in obsessive-
compulsive disorder or post-traumatic stress disorder, and
there is no evidence of long-term effectiveness in any anx-
iety disorder [46]. BZDs are not recommended as a first-
line treatment in any anxiety disorder because of the con-
troversy over whether the short-term benefits outweigh
the risk of dependence and side effects, which include
daytime drowsiness, impairment of learning, psychomotor
slowing and increased risk of accidents [46]. BZDs may
also cause paradoxical reactions, including increased anx-
iety, agitation, hyperactivity and aggressiveness, and the
risk of these is increased in people with personality and
substance use disorders [46]. Therefore, it is alarming that
BZD use was particularly common in people with person-
ality and substance use disorders. The results suggest that
more attention should be paid to prescription of BZDs to
people with anxiety disorders in Finland.
In our study, 11.0 % of participants discontinued the
visits, but none of the sociodemographic factors or comor-
bidities were related to dropout. This is in line with a re-
view of Santana and Fontenelle, who found the prevalence
of dropouts varied from 10.3 to 57.0 % in different studies.
They also stated that no consistent conclusion can be
reached regarding the effect of sociodemographic factors
and clinical features on adherence of patients, though they
emphasized the significance of cognitive variables, such as
expectations and beliefs about the disease and its treat-
ment, in managing patients with anxiety disorders [47].
The main strength of this study was a two-phase study
design which enabled us to conduct SCID-I interviews,
which were done by experienced mental health profes-
sionals. We also had access to case records from all men-
tal health treatments, which compensated for any possible
effect of recall bias in the final diagnostic assessment.
Therefore we cannot directly compare our results with
most previous surveys using only information collected by
interviews. The percentage of minimally adequate treat-
ment was slightly smaller (37.1 %) when we excluded
those patients who had not been interviewed, for whom
we only had medical records.
Regarding limitations, they have also been discussed in
detail in our previous article which focused on the treat-
ment of depressive disorders [27]. To summarize: attri-
tion is the main limitation of a two-phase study design
[48]. In this study, attrition, both in the questionnaire
and the interview, was associated with age, gender, edu-
cation and hospital treatment, but not with self-reported
mental health disorders or symptoms at the baseline sur-
vey. A more detailed analysis of nonresponse has been
reported previously [26].
Table 8 Variables associated with benzodiazepine use during
the most recent treatment period for anxiety disordersb, c
Benzodiazepine
prescribed
Variable Category OR 95 % CI
Gender Male (ref.) 1.00 -
Female 0.66 0.16–2.63
Basic education Less than high school (ref.) 1.00 -
High school 1.46 0.37–5.81
Married or No (ref.) 1.00 -
cohabiting Yes 0.94 0.29–3.08
Comorbid No (ref.) 1.00 -
mood disorder Yes 0.66 0.20–2.21
Comorbid substance No (ref.) 1.00 -
use disorder Yes 2.30 0.57–9.26
Comorbid No (ref.) 1.00 -
personality disorder Yes *4.77 1.11–20.59
Comorbid No (ref.) 1.00 -
other disordera Yes 1.72 0.39–7.47
More than 1 anxiety No (ref.) 1.00 -
disorder Yes 0.45 0.08–2.65
OR Adjusted odds ratio; 95 % CI 95 % confidence interval
*p < 0.05; **p < 0.01; ***p < 0.001. These p-values indicate a significance of the
difference of the odds ratios between categories tested by χ2-test. Significant
differences (p < 0.05) in boldface
aPsychotic, eating, sleeping, adjustment or impulse control disorder lifetime
bParticipants with a single specific phobia were excluded
cAll the variables were entered simultaneously into a logistic regression model,
adjusting for the other factors shown in the table
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Another notable limitation was a small size of the
study sample, which led to low statistical power. This
was also a reason why we could not analyze the treat-
ments for each anxiety disorder separately. Moreover,
correction for multiple testing was not done.
A minor limitation is that SCID-II was not used in the
interview. The diagnostic assessment of personality disor-
ders was based on other available systematically evaluated
information from the interview and/or case records by ex-
perienced clinicians.
Psychotherapy in this study means psychosocial support
broadly, because we did not have information on whether
the mental health professional providing treatment was a
licensed psychotherapist. Therefore, we cannot draw con-
clusions on the access to actual psychotherapy on the
basis of this study.
The Mental Health in Early Adulthood in Finland
(MEAF) study was carried out about 10 years ago. Based
on official statistics, the use of antidepressants and the
number of psychiatric outpatient visits has increased and
also the availability of psychotherapy is better in Finland
nowadays. Therefore, the figures of minimally adequate
treatment may be better today.
Conclusions
More efforts are needed to treat young adults with anxiety
disorders, since less than a half of them received minim-
ally adequate treatment, though more than 70 % seek
treatment. Benzodiazepine use was more frequent among
individuals with personality and substance use disorders,
who may be especially vulnerable to their negative effects.
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